Zimmer Biomet (NYSE:ZBH) Announces Earnings Results, Beats Estimates By $0.01 EPS

Zimmer Biomet (NYSE:ZBH) announced its quarterly earnings results on Thursday. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01, RTT News reports. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the business posted $2.20 EPS. Zimmer Biomet updated its FY 2025 guidance to 8.150-8.350 EPS.

Zimmer Biomet Stock Performance

ZBH stock traded down $1.68 during midday trading on Friday, hitting $101.01. 2,803,610 shares of the company traded hands, compared to its average volume of 1,765,066. The business has a 50 day simple moving average of $107.34 and a 200-day simple moving average of $108.10. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet has a twelve month low of $99.93 and a twelve month high of $133.90. The stock has a market capitalization of $20.11 billion, a price-to-earnings ratio of 22.70, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday. Wells Fargo & Company increased their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Stifel Nicolaus boosted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday. Finally, JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $124.70.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.